scispace - formally typeset
Search or ask a question
Author

Radhakrishnan P. Iyer

Bio: Radhakrishnan P. Iyer is an academic researcher from Hybridon, Inc. The author has contributed to research in topics: Oligonucleotide synthesis & Oligonucleotide. The author has an hindex of 25, co-authored 116 publications receiving 1850 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: The hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of olig onucleotides, a finding that may be important in the development of antisense oligon nucleotides as therapeutic agents.

146 citations

Journal ArticleDOI
TL;DR: Several isosteric analogs of phosphoric diester oligonucleotides with neutral achiral backbones, and other novel molecules, such as peptide nucleic acids and circular oligon DNA, are reported to form stable duplexes with complementary RNA/DNA and are currently under investigation.

128 citations

Journal ArticleDOI
TL;DR: In vivo biostability, disposition, and excretion of a 25-mer hybrid oligonucleotide were determined in rats after i.v. bolus administration of the 35S-labeled oligon nucleotide at a dose of 30 mg/kg and analysis by HPLC showed that the majority of the radioactivity in tissues was associated with the intact hybrid olig onucleotide.

92 citations

Journal ArticleDOI
TL;DR: In this paper, the synthesis of the nucleoside phosphoramidite 6 by reaction of the chiral oxazaphospholidine 4 with 5′-DMT-T is reported.
Abstract: The stereoselective synthesis of the nucleoside phosphoramidite 6 by reaction of the chiral oxazaphospholidine 4 with 5′-DMT-T is reported. The novel phosphoramidite synthon, 6 , is stereoselectively converted to 8 by oxidative sulfurization with 1 . The oxazaphospholidines, 6 and 8 , are a new class of potential nucleoside synthons for the synthesis of oligonucleotides.

68 citations

Journal ArticleDOI
TL;DR: The present review will provide an overview of the pharmacokinetics and toxicology following intravenous, intraperitoneal, subcutaneous and oral administration of mixed-backbone oligos as second-generation antisense therapeutics.

65 citations


Cited by
More filters
Patent
09 Jul 2004
TL;DR: In this paper, nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed.
Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.

776 citations

Journal ArticleDOI
TL;DR: Locked nucleic acid is an RNA derivative in which the ribose ring is constrained by a methylene linkage between the 2'-oxygen and the 4'-carbon that increases binding affinity for complementarity sequences and provides an exciting new chemical approach for the control of gene expression and optimization of microarrays.

754 citations

Patent
14 Nov 2002
TL;DR: In this paper, the authors define compounds having structure (1) where R 1 is a protecting group, a linker or a binding partner; and R 2 and R 34 are as defined in the specification.
Abstract: Compounds having structure (1) wherein R 1 is —H a protecting group, a linker or a binding partner; and R 2 and R 34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.

642 citations

Journal ArticleDOI
TL;DR: A review of solid-phase organic synthesis can be found in this article, where the authors discuss the use of reagents and scavenging reagents in the context of solid phase organic synthesis (SPOS).
Abstract: 1 Review 1.1 Overview 1.2 Solid-phase organic synthesis (SPOS) 1.3 Beyond conventional solid-phase organic synthesis 1.4 The review 1.5 Some definitions 1.6 Solid-supported reagents and scavengers 1.7 Multi-step use of solid-supported reagents and scavenging reagents 1.8 Conclusions and future perspective 2 Introduction to the tables 2.1 Organisation of tables (reagent and catalyst section) 2.2 Representative data entry (reagent and catalyst section) 2.3 Organisation of tables (scavenging agents section) 2.4 Representative data entry (scavenging agents section) 3 Tables of reagents and catalysts 4 Tables of scavengers 5 Other relevant reviews 5.1 Insoluble polymers 5.1.1 Structure and physical properties (insoluble polymers) 5.1.2 General (insoluble polymers) 5.1.3 Reactions (insoluble polymers) 5.1.4 Miscellaneous (insoluble polymers) 5.2 Soluble polymers 5.2.1 General (soluble polymers) 5.2.2 Reactions (soluble polymers) 5.3 Inorganic solids 5.3.1 Structure and physical properties (inorganic solids) 5.3.2 General (inorganic solids) 5.3.3 Reactions (inorganic solids) 5.3.4 Miscellaneous (inorganic solids) 5.4 Miscellaneous supports 5.4.1 Structure and physical properties (miscellaneous supports) 5.4.2 General (miscellaneous supports) 5.4.3 Reactions (miscellaneous supports) 5.4.4 Miscellaneous (miscellaneous supports) 5.5 Purification strategies 5.5.1 Various supports (purification strategies) 5.5.2 Insoluble polymers (purification strategies) 6 Acknowledgements 7 Abbreviations 8 References 1 Review

623 citations

Journal ArticleDOI
TL;DR: The experience gained is providing a basis for designing a second generation of antisense oligonucleotides, which have the ability to selectively block disease-causing genes and inhibiting production of disease-associated proteins.

503 citations